* Cara Therapeutics Inc reported a quarterly adjusted loss of 23 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -52 cents. The mean expectation of three analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -26 cents to -23 cents per share.
* Revenue fell 47.5% to $2.56 million from a year ago; analysts expected $1.62 million.
* Cara Therapeutics Inc's reported EPS for the quarter was a loss of 23 cents.
* The company reported a quarterly loss of $12.48 million.
* Cara Therapeutics Inc shares had risen by 6.4% this quarter and lost 55.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 1.7% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "hold"
Wall Street's median 12-month price target for Cara Therapeutics Inc is $1.01 This summary was machine generated from LSEG data November 15 at 02:07 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.25 -0.23 Beat
Jun. 30 2024 -0.27 -0.37 Missed
Mar. 31 2024 -0.40 -0.56 Missed
Dec. 31 2023 -0.41 -0.59 Missed
Comments